The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population

被引:18
|
作者
Seo, Ji Yeon [1 ]
Cho, Eun Ju [2 ]
Kim, Min Joo [3 ]
Kwak, Min-Sun [1 ]
Yang, Jong In [1 ]
Chung, Su Jin [1 ]
Yim, Jeong Yoon [1 ]
Yoon, Ji Won [3 ]
Chung, Goh Eun [1 ]
机构
[1] Seoul Natl Univ Hosp, Internal Med & Healthcare Res Inst, Dept Gastroenterol & Hepatol, Healthcare Syst Gangnam Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Internal Med & Liver Res Inst, Dept Gastroenterol & Hepatol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Internal Med & Healthcare Res Inst, Dept Endocrinol, Healthcare Syst Gangnam Ctr, Seoul, South Korea
关键词
fibrosis; hepatic steatosis; low muscle mass; metabolic dysfunction; CONTROLLED ATTENUATION PARAMETER; INSULIN-RESISTANCE; HEPATIC STEATOSIS; SARCOPENIA; FIBROSIS; OBESITY;
D O I
10.1002/jcsm.13099
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Metabolic (dysfunction)-associated fatty liver disease (MAFLD) emphasizes the metabolic dysfunction in nonalcoholic fatty liver disease (NAFLD). Although the relationship between low muscle mass and NAFLD has been suggested, the effect of MAFLD on low muscle mass is yet to be investigated. In this study, we examined the relationship between MAFLD and low muscle mass in an asymptomatic Korean population. Methods Examinees who underwent FibroScan (R) and bioelectrical impedance analyses on the same day during the period of June 2017 to December 2019 were included. Hepatic steatosis was diagnosed using controlled attenuation parameter (CAP) with two cut-off values of 248 and 294 dB/m. Low muscle mass was defined based on appendicular skeletal muscle mass/body weight (wt) or body mass index (BMI) ratios of two standard deviations below the sex-specific mean for healthy young adults. Subjects were divided into four subgroups: diabetic MAFLD (presence of diabetes mellitus [DM]), metabolic dysfunction (MD) MAFLD (=2 metabolic abnormalities without DM), overweight MAFLD (overweight/obese without DM and <2 metabolic abnormalities) and no MAFLD. Results Among all of the 6414 subjects (mean 53.9 years of age; 85.4% male), the prevalence of MAFLD was 49.9% and 22.7% for CAP cut-off values of 248 and 294 dB/m, respectively. In the multivariate analysis, MAFLD was associated with an increased risk of both low muscle mass_wt (odds ratio [OR] 1.80, 95% confidence interval [CI] 1.38-2.35, P < 0.001) and low muscle mass_BMI (OR 1.31, 95% CI 1.01-1.70, P = 0.042). The risk of low muscle mass_wt and low muscle mass_BMI increased the most in the diabetic MAFLD subgroup compared with the no-MAFLD group (OR 2.11, 95% CI 1.51-2.96, P < 0.001 and OR 1.51, 95% CI 1.08-2.13, P = 0.017). There was an increased risk of low muscle mass_wt in the MD MAFLD subgroup (OR 1.73, 95% CI 1.31-2.28, P < 0.001). Comparable results were observed when the CAP cut-off value of 294 dB/m was applied. Conclusions The presence of MAFLD is significantly associated with increased risk of low muscle mass with varying risks according to the MAFLD subgroups. Clinicians should be aware of the differentiated risk of low muscle mass across the subgroups of MAFLD.
引用
收藏
页码:2953 / 2960
页数:8
相关论文
共 50 条
  • [41] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Maurice Michel
    Christian Labenz
    Angelo Armandi
    Leonard Kaps
    Wolfgang Maximilian Kremer
    Peter R. Galle
    Daniel Grimm
    Martin Sprinzl
    Jörn M. Schattenberg
    Scientific Reports, 13
  • [42] Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
    Hwang, Tae-In
    Han, A-Lum
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [43] Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
    Alam, Shahinul
    Fahim, Shah Mohammad
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (10) : 1203 - 1207
  • [44] Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
    Shahinul Alam
    Shah Mohammad Fahim
    World Journal of Hepatology, 2021, 13 (10) : 1203 - 1207
  • [45] Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children
    Rupasinghe, Kushila
    Hind, Jonathan
    Hegarty, Robert
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (05): : 583 - 591
  • [46] Are dairy products the answer to metabolic dysfunction-associated fatty liver disease?
    Lau, Kristopher Cho-Hei
    Wong, Vincent Wai-Sun
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 870 - 872
  • [47] Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B
    Huang, Shang -Chin
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2148 - 2151
  • [48] Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
    Al Hashmi, Khamis
    Giglio, Rosaria Vincenza
    Stoian, Anca Pantea
    Patti, Angelo Maria
    Al Waili, Khalid
    Al Rasadi, Khalid
    Ciaccio, Marcello
    Rizzo, Manfredi
    FRONTIERS IN NUTRITION, 2024, 11
  • [49] Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Song, Byeong Geun
    Choi, Sung Chul
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Seung Woon
    JHEP REPORTS, 2023, 5 (09)
  • [50] Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
    Jung, Han Na
    Jung, Chang Hee
    DIABETES & METABOLISM JOURNAL, 2023, 47 (02) : 198 - 200